These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 21471168)

  • 21. Hypothesis: Extra-hepatic acromegaly: a new paradigm?
    Neggers SJ; Kopchick JJ; Jørgensen JO; van der Lely AJ
    Eur J Endocrinol; 2011 Jan; 164(1):11-6. PubMed ID: 21045065
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Exercise-induced microalbuminuria in patients with active acromegaly: acute effects of slow-release lanreotide, a long-acting somatostatin analog.
    Manelli F; Bossoni S; Burattin A; Doga M; Solerte SB; Romanelli G; Giustina A
    Metabolism; 2000 May; 49(5):634-9. PubMed ID: 10831175
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inflammatory adipokines contribute to insulin resistance in active acromegaly and respond differently to different treatment modalities.
    Olarescu NC; Ueland T; Godang K; Lindberg-Larsen R; Jørgensen JO; Bollerslev J
    Eur J Endocrinol; 2014 Jan; 170(1):39-48. PubMed ID: 24092547
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The relationship between 24-hour growth hormone secretion and insulin-like growth factor I in patients with successfully treated acromegaly: impact of surgery or radiotherapy.
    Peacey SR; Toogood AA; Veldhuis JD; Thorner MO; Shalet SM
    J Clin Endocrinol Metab; 2001 Jan; 86(1):259-66. PubMed ID: 11232010
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Discordant nadir GH after oral glucose and IGF-I levels on treated acromegaly: refining the biochemical markers of mild disease activity.
    Elias PC; Lugao HB; Pereira MC; Machado HR; Castro Md; Moreira AC
    Horm Metab Res; 2010 Jan; 42(1):50-5. PubMed ID: 19798623
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cardiovascular effects of a single slow release lanreotide injection in patients with acromegaly and left ventricular hypertrophy.
    Manelli F; Desenzani P; Boni E; Bugari G; Negrini F; Romanelli G; Grassi V; Giustina A
    Pituitary; 1999 Nov; 2(3):205-10. PubMed ID: 11081155
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Outcome of somatostatin analogue treatment in acromegaly].
    Mondok A; Tóth M; Patócs A; Szücs N; Igaz P; Pusztai P; Czirják S; Beko G; Gláz E; Rácz K; Tulassay Z
    Orv Hetil; 2009 Aug; 150(31):1457-62. PubMed ID: 19617182
    [TBL] [Abstract][Full Text] [Related]  

  • 28. GH replacement improves quality of life and metabolic parameters in cured acromegalic patients with growth hormone deficiency.
    Giavoli C; Profka E; Verrua E; Ronchi CL; Ferrante E; Bergamaschi S; Sala E; Malchiodi E; Lania AG; Arosio M; Ambrosi B; Spada A; Beck-Peccoz P
    J Clin Endocrinol Metab; 2012 Nov; 97(11):3983-8. PubMed ID: 22904173
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The value of an acute octreotide suppression test in predicting response to long-term somatostatin analogue therapy in patients with acromegaly.
    Bandgar TR; Sarathi V; Shivane V; Bansode N; Menon PS; Shah NS
    J Postgrad Med; 2010; 56(1):7-11. PubMed ID: 20393242
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A single-dose comparison of the acute effects between the new somatostatin analog SOM230 and octreotide in acromegalic patients.
    van der Hoek J; de Herder WW; Feelders RA; van der Lely AJ; Uitterlinden P; Boerlin V; Bruns C; Poon KW; Lewis I; Weckbecker G; Krahnke T; Hofland LJ; Lamberts SW
    J Clin Endocrinol Metab; 2004 Feb; 89(2):638-45. PubMed ID: 14764775
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of treating acromegaly first with surgery or somatostatin analogs on cardiomyopathy.
    Colao A; Pivonello R; Galderisi M; Cappabianca P; Auriemma RS; Galdiero M; Cavallo LM; Esposito F; Lombardi G
    J Clin Endocrinol Metab; 2008 Jul; 93(7):2639-46. PubMed ID: 18445662
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pasireotide (SOM230) demonstrates efficacy and safety in patients with acromegaly: a randomized, multicenter, phase II trial.
    Petersenn S; Schopohl J; Barkan A; Mohideen P; Colao A; Abs R; Buchelt A; Ho YY; Hu K; Farrall AJ; Melmed S; Biller BM;
    J Clin Endocrinol Metab; 2010 Jun; 95(6):2781-9. PubMed ID: 20410233
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Discontinuation of octreotide LAR after long term, successful treatment of patients with acromegaly: is it worth trying?
    Ramírez C; Vargas G; González B; Grossman A; Rábago J; Sosa E; Espinosa-de-Los-Monteros AL; Mercado M
    Eur J Endocrinol; 2012 Jan; 166(1):21-6. PubMed ID: 21993154
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Magnetic resonance imaging as a predictor of response to somatostatin analogs in acromegaly after surgical failure.
    Puig-Domingo M; Resmini E; Gomez-Anson B; Nicolau J; Mora M; Palomera E; Martí C; Halperin I; Webb SM
    J Clin Endocrinol Metab; 2010 Nov; 95(11):4973-8. PubMed ID: 20739382
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term biochemical status and disease-related morbidity in 53 postoperative patients with acromegaly.
    Serri O; Beauregard C; Hardy J
    J Clin Endocrinol Metab; 2004 Feb; 89(2):658-61. PubMed ID: 14764777
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Place of cabergoline in acromegaly: a meta-analysis.
    Sandret L; Maison P; Chanson P
    J Clin Endocrinol Metab; 2011 May; 96(5):1327-35. PubMed ID: 21325455
    [TBL] [Abstract][Full Text] [Related]  

  • 37. GH and IGF-I excess control contributes to blood pressure control: results of an observational, retrospective, multicentre study in 105 hypertensive acromegalic patients on hypertensive treatment.
    Colao A; Terzolo M; Bondanelli M; Galderisi M; Vitale G; Reimondo G; Ambrosio MR; Pivonello R; Lombardi G; Angeli A; degli Uberti EC
    Clin Endocrinol (Oxf); 2008 Oct; 69(4):613-20. PubMed ID: 18410555
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetic-pharmacodynamic comparison of a novel multiligand somatostatin analog, SOM230, with octreotide in patients with acromegaly.
    Ma P; Wang Y; van der Hoek J; Nedelman J; Schran H; Tran LL; Lamberts SW
    Clin Pharmacol Ther; 2005 Jul; 78(1):69-80. PubMed ID: 16003295
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunoreactivity score using an anti-sst2A receptor monoclonal antibody strongly predicts the biochemical response to adjuvant treatment with somatostatin analogs in acromegaly.
    Gatto F; Feelders RA; van der Pas R; Kros JM; Waaijers M; Sprij-Mooij D; Neggers SJ; van der Lelij AJ; Minuto F; Lamberts SW; de Herder WW; Ferone D; Hofland LJ
    J Clin Endocrinol Metab; 2013 Jan; 98(1):E66-71. PubMed ID: 23118420
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Serum leptin levels in patients with acromegaly before and after correction of hypersomatotropism by trans-sphenoidal surgery.
    Damjanović SS; Petakov MS; Raicević S; Micić D; Marinković J; Dieguez C; Casanueva FF; Popović V
    J Clin Endocrinol Metab; 2000 Jan; 85(1):147-54. PubMed ID: 10634378
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.